EUVIMEDEUVIMED entdecken
Crossref

Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer

Nan Zhong, Ziyue Zu, Yishi Lu, Xuan Sha, Yang Li, Yang Liu, Shangyu Lu, Xi Luo, Yan Zhou, Jun Tao, Feiyun Wu, Zhaogang Teng und 2 weitere

Acta Biomaterialia · 2025

DOI: 10.1016/j.actbio.2025.04.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Nan Zhong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Imaging, Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Nucleotidyltransferases, Silicon Dioxide, Mitochondria. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway could effectively initiate antitumor immunity in triple-negative breast cancer. However, current nuclear DNA-mediated activation of STING pathway remains constrained by the tight protection of nuclear membrane and histones, highlighting the need for new strategies to enhance its efficacy. Mitochondrial DNA (mtDNA), in contrast, is more vulnerable to damage. Herein, our nanoplatforms exploited the high glutathione (GSH) environment characteristic of tumors to release abundant Mnb+, which induced mitochondrial dysfunction and the release of endogenous mtDNA. The released mtDNA, in conjunction with Mnb+ itself functioning as a strong cGAS agonist, effectively activated cGAS-STING pathway. Consequently, the cGAS-STING-dependent secretion of type I interferon successively enhanced the maturation of dendritic cells and cross-priming of CD8+ T cells. In a poorly immunogenic 4T1 tumor model, TPP-MMONs efficiently primed systemic antitumor immunity and significantly enhanced the therapeutic efficacy of αPD-L1 therapy, suppressing tumor growth in both localized and metastatic tumor models. These findings provided an innovative and straightforward strategy to enhance TNBC immunogenicity by targeting mitochondrial damage to induce mtDNA-mediated cGAS-STING activation, thereby sensitizing tumors to immune checkpoint inhibitor therapy. STATEMENT OF SIGNIFICANCE: The cGAS-STING pathway is a promising target for overcoming immunoresistance in TNBC. However, current nuclear DNA-based activation strategies are limited by the tight protection of nuclear membrane and histones. Herein, we reported novel manganese-rich, mitochondria-targeting nanoplatforms (TPP-MMONs), which can release abundant Mn²⁺ and significantly induce mitochondrial dysfunction, leading to the release of mtDNA. As a result, the nanoplatforms can effectively stimulate the cGAS-STING pathway, thereby enhancing immune responses and improving the therapeutic efficacy of αPD-L1 therapy, offering new insights into TNBC treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsNucleotidyltransferasesSilicon DioxideMitochondriaMembrane ProteinsManganeseNanoparticlesB7-H1 AntigenImmune Checkpoint InhibitorsAnimalsFemaleMiceHumansCell Line, TumorMice, Inbred BALB CPorosityDNA, MitochondrialSignal TransductionCD8-Positive T-LymphocytesCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseSTING Protein

Stichwörter der Autor:innen

CGAS-STING pathwayImmunotherapyManganeseMitochondrial DNANanomedicine

Substanzen

NucleotidyltransferasesSilicon DioxideMembrane ProteinsManganeseB7-H1 AntigenDNA, MitochondrialImmune Checkpoint InhibitorscGAS protein, mouseCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseSting1 protein, mouse

Autor:innen und Institutionen

  • Laboratory of Molecular Imaging, Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Department of Interventional Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • Key Laboratory for Organic Electronics and Information Displays and Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials, Jiangsu National Synergetic Innovation Centre for Advanced Materials, Nanjing U…
  • Laboratory of Molecular Imaging, Department of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Electronic address: wangshouju@njmu.edu.cn.

Förderung

  • Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
  • National Natural Science Foundation of China

Zitieren

APA

Zhong, N., Zu, Z., Lu, Y., Sha, X., Li, Y., Liu, Y., Lu, S., Luo, X., Zhou, Y., Tao, J., Wu, F., Teng, Z., Tang, Y., & Wang, S. (2025). Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.04.040

Vancouver

Zhong N, Zu Z, Lu Y, Sha X, Li Y, Liu Y, et al. Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.04.040

BibTeX
@article{Zhong2025,
  author = {Zhong, Nan and Zu, Ziyue and Lu, Yishi and Sha, Xuan and Li, Yang and Liu, Yang and Lu, Shangyu and Luo, Xi and Zhou, Yan and Tao, Jun and Wu, Feiyun and Teng, Zhaogang and Tang, Yuxia and Wang, Shouju},
  title = {Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer},
  journal = {Acta Biomaterialia},
  year = {2025},
  doi = {10.1016/j.actbio.2025.04.040}
}
Kostenlos starten →